Regeneron and Sanofi Announce FDA Approval of Dupixent for Treatment of Bullous Pemphigoid in Adults

The FDA has approved Dupixent (dupilumab) for treating adult patients with bullous pemphigoid (BP), a chronic skin disease, based on trial data showing significant improvements in sustained disease remission and itch reduction compared to placebo; specifically, 18.3% of patients on Dupixent experienced sustained remission versus 6.1% on placebo. Dupixent, developed by Regeneron and Sanofi, is now approved for eight distinct diseases driven by type 2 inflammation, potentially expanding its market reach, though common side effects include joint pain and eye issues. Recent congressional trading activity shows members of congress have traded $REGN stock 10 times in the past 6 months, with more sales than purchases.

Analysis

The U.S. Food and Drug Administration's approval of Dupixent (dupilumab), co-developed by Regeneron (REGN) and Sanofi (SNY), for adult bullous pemphigoid (BP) marks a significant expansion for the drug, now authorized for eight distinct diseases driven by type 2 inflammation. Pivotal ADEPT trial data demonstrated Dupixent's efficacy in BP, with 18.3% of patients achieving sustained disease remission at 36 weeks compared to 6.1% on placebo (a 12.2% difference), and 38.3% experiencing clinically meaningful itch reduction versus 10.5% on placebo, alongside a reduction in median cumulative oral corticosteroid use to 2.8 grams from 4.1 grams. This approval, which received Priority Review and Orphan Drug Designation, targets an estimated 27,000 U.S. adults with BP, highlighting an unmet medical need. While Dupixent's safety profile includes common adverse events such as arthralgia and conjunctivitis, and noted risks of serious side effects including one reported case of acute generalized exanthematous pustulosis, its benefits in managing BP are substantial. For Regeneron (REGN), Wall Street sentiment is positive, evidenced by four recent buy-equivalent ratings and a median price target of $802.5. However, institutional holdings data for REGN from Q1 2025 indicates a mixed picture: 648 institutional investors added shares while 771 decreased positions, with significant divestments by JPMORGAN CHASE & CO (-19.8%) and CAPITAL WORLD INVESTORS (-30.2%), contrasted by large new or increased investments from TWO SIGMA ADVISERS, LP and GOLDMAN SACHS GROUP INC (+77.3%). Congressional trading activity for REGN over the past six months showed 8 sales versus 2 purchases by members of Congress.

Key Decisions for Investors

• The FDA approval for bullous pemphigoid significantly enhances Dupixent's market potential and reinforces its role as a key revenue driver for Regeneron and Sanofi, supporting a positive outlook based on strong clinical efficacy in an underserved patient population.
• Investors in Regeneron ($REGN) should closely monitor upcoming quarterly institutional holding disclosures to discern evolving sentiment among large funds, given the divergent significant buying and selling activities observed in Q1 2025, and also track post-market safety data and commercial uptake of Dupixent in the bullous pemphigoid indication.
• While the consensus among Wall Street analysts for Regeneron is constructive, with multiple buy ratings and a median price target of $802.5, it is prudent to weigh potential risks such as the drug's adverse event profile and the evolving competitive landscape for treatments targeting type 2 inflammation.
• The observed net selling of $REGN stock by members of Congress in recent months is a data point to consider, although its significance should be contextualized against broader institutional investment trends and fundamental company developments.